Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
Salma M AlDallal Haematology Laboratory, Amiri Hospital, Kuwait City, Kuwait Abstract: Ofatumumab Arzerra® is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and anti...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-07-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/ofatumumab-a-valid-treatment-option-for-chronic-lymphocytic-leukemia-p-peer-reviewed-article-TCRM |